Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
UCB’s 90-year book is a goldmine to discover!
Twitter Feed
-
Our new five-year collaboration with the UK @epilepsysociety aims to address needs of people with epilepsy who do not respond to currently available treatments. Find out more about it here: https://t.co/p1Rr0oqLEO #StrongerTogether #HarnessingGenetics
— UCB News (@ucb_news) 18.02.2019 -
#Epilepsy is the most common serious neurological condition, affecting more than half a million people in the UK. That is why UCB is collaborating with @epilepsysociety to address this problem. https://t.co/p1Rr0oqLEO #ProudPartners #HarnessingGenetic
— UCB News (@ucb_news) 14.02.2019 -
Find out more about our new genomic partnership with the UK @epilepsysociety – which follows UCB’s commitment to invest £1 billion into the UK life-sciences sector over the next five years. https://t.co/p1Rr0oqLEO #StrongerTogether #HarnessingGenetics #
— UCB News (@ucb_news) 13.02.2019
Highlights
At UCB, we take our responsibility to the planet very seriously.
UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. Discove more...
